Anti-arthritis drug, Milican inj. on clinical phase IIb.

Published: 2001-02-01 17:31:00

Updated: 2001-02-01 17:31:00

Dongwha Pharmaceutical company announced that Milican inj. a new anti-rheumatoid arthritis agent, completed its clinical phase I and IIa studies, and the phase IIb study seemed to follow soon according to the KFDA's approval.

Milican inj. has been developed by Dongwha in technical cooperation with Korea Institute of Nuclear Power (President: Chang In-soon), as the new compound Dongwha has de...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.